Saturday 17 October 2026
Export NEXI’s income statement to Excel — free account
NexImmune, Inc.
NEXI Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow NEXI
| Jun '24 | Mar '24 | Dec '23 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
| (232.97%) | (196.47%) | (180.64%) | (156.79%) |
+8 more TTM periods Free account |
|
| (140.56%) | (130.41%) | (125.24%) | (121.49%) | ||
ROIC |
0.00% | 0.00% | (7,175.68%) | 0.00% | |
Return on Tangible Assets |
4,097.97% | (977.31%) | (1,937.14%) | (561.05%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(12.34) | (16.83) | (29.99) | (35.22) | |
Free Cash Flow |
(17.04) | (21.04) | (31.47) | (36.91) | |
Capital Expenditures |
0.57 | 0.52 | (0.04) | (0.19) | |
| Other line items | |||||
Cash ROIC |
(542.46%) | (291.61%) | (467.53%) | (213.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.48 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 181.47 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | (46.09) | |
Operating CF/Net income |
0.85 | 0.83 | 0.97 | 0.84 | |
Depreciation/Fixed assets |
0.62 | 0.71 | 0.76 | 0.29 | |
Capex/Depreciation |
0.83 | 0.59 | (0.04) | (0.18) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(12.76) | (17.24) | (29.95) | (35.04) | |
Capex per Share |
0.41 | 0.42 | (0.04) | (0.18) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates